Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Renal pelvis and ureter cancer
Stage/Subtype:  recurrent transitional cell cancer of the renal pelvis and ureter
Trial Type:  Treatment
Results 1-25 of 33 for your search:
Start Over
Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-361, NCI-2016-01926, 163458, 2015-005731-41, NCT02853305
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: INCB 54828-101, NCI-2015-00611, NCT02393248
A Phase 1b/2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: B-701-U21, NCI-2015-00701, NCT02401542
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1128-CA, NCI-2016-00449, NCT02599324
Radiation Therapy in Preventing Brain Metastases in Patients with Locally Advanced or Metastatic Bladder or Urinary Tract Cancer Previously Treated with Chemotherapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2007-0933, NCI-2012-01675, NCT00756639
Tesetaxel for Previously Treated Patients With Bladder Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TOBL204, NCI-2011-02438, NCT01215877
Gemcitabine Hydrochloride, Cisplatin, and Ipilimumab as First-Line Therapy in Treating Patients With Metastatic Urothelial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GU10-148, NCI-2013-00250, 1110007307, NCT01524991
Palbociclib in Treating Patients with Metastatic Urothelial Cancer after First-Line Chemotherapy Failure
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 1406, NCI-2015-00532, 14-2196, WI187190, NCT02334527
Chemotherapy before Surgery in Treating Patients with High Grade Upper Urinary Tract Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA8141, NCI-2014-02267, NCT02412670
Nivolumab with or without Ipilimumab in Treating Patients with Advanced or Metastatic Melanoma or Bladder Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-126, NCI-2015-01786, NCT02553642
Paclitaxel and Pembrolizumab in Treating Patients with Refractory Metastatic Urothelial Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CCCWFU 88215, NCI-2015-01713, NCT02581982
Genomic Based Assignment of Therapy in Treating Patients with Progressive Metastatic Urothelial Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: P152399, NCI-2016-00966, 16-C-0121, NCT02788201
A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Urothelial Carcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: INCB 54828-201, NCI-2016-01513, NCT02872714
Sapanisertib in Treating Patients with Locally Advanced or Metastatic Bladder Cancer with TSC1 and/or TSC2 Mutations
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 9767, NCI-2015-00121, 1505015958, NCT03047213
Atezolizumab, Gemcitabine Hydrochloride, and Cisplatin as First-Line Therapy in Treating Patients with Locally Advanced or Metastatic Urothelial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-1621, NCI-2017-00748, NCT03093922
Nivolumab in Treating Patients with Stage II-IV Muscle-Invasive Bladder, Urethra, or Ureter Cancer That Have Undergone Chemoradiotherapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: HCI100769, NCI-2017-01197, CA209-999, NEXT, NCT03171025
Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8808, NCI-2011-02500, CDR0000700997, UPCI 10-115, NCT01366144
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EMR 100070-001, NCI-2013-02214, 2013-002834-19, NCT01772004
A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ASG-22CE-13-2, NCI-2014-01228, NCT02091999
Enzalutamide in Combination with Gemcitabine Hydrochloride and Cisplatin in Treating Patients with Locally Advanced or Metastatic Stage IV Bladder Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-17924, NCI-2015-00231, NCT02300610
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients with Previously Treated Advanced or Metastatic Urothelial Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UCDCC#252, NCI-2015-00426, NCT02437370
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15787, NCI-2015-01802, 2015-001473-40, I4T-MC-JVDF, KEYNOTE -098, NCT02443324
Start Over